Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jul 19, 2013
First Patient Treated in OPTIMISE Clinical Trial Evaluating Safety, Efficacy of Occipital Nerve Stimulation Using Precision™ System Boston Scientific Corporation (NYSE: BSX) has launched a...
-
Jul 19, 2013Boston Scientific Launches Trial To Evaluate Neurostimulation For Treatment Of Chronic Migraine [EN]First Patient Treated in OPTIMISE Clinical Trial Evaluating Safety, Efficacy of Occipital Nerve Stimulation Using Precision™ System
Boston Scientific Corporation (NYSE: BSX) has launched a clinical trial to determine whether occipital nerve stimulation (ONS) using the Precision™ System can safely and effectively treat...
-
Jun 28, 2013Transaction to Accelerate Boston Scientific Expansion in Growing Electrophysiology Market
In a move that would significantly boost its capabilities in the fast-growing market for advanced electrophysiology procedures, Boston Scientific Corporation (NYSE:BSX) has entered into a...
-
Jun 26, 2013
The first patient implant of the Boston Scientific Corporation (NYSE: BSX) VITALIO™ pacemaker was performed at ZGT Hengelo in Hengelo, the Netherlands. In addition to a comprehensive suite of...
-
Jun 25, 2013
Boston Scientific Corporation (NYSE: BSX) is launching a new family of pacemakers in Europe. These pacemakers monitor respiration, adjust pacing accordingly, and support insight into the patient?s...
-
Jun 24, 2013Outcomes Follow Recent NICE Guidance Supporting Safety and Effectiveness of Subcutaneous Implantable Defibrillators
The Boston Scientific Corporation (NYSE:BSX) S-ICD® (subcutaneous implantable defibrillator) System showed a significant reduction in major lead-related complications when compared with both...
-
May 28, 2013
Boston Scientific Corporation (NYSE: BSX) presenta i risultati positivi di due studi clinici riguardanti nuove ed innovative tecnologie di stent medicati (DES), che rappresentano opzioni...
-
May 28, 2013Nuovi dati clinici sono stati presentati durante l'EuroPCR nel corso di una Late Breaking Clinical Trial Session e hanno dimostrato risultati positivi in termini di minino rigurgito paravalvolare, a 30 giorni, nei primi 60 pazienti trattati con la valvola Lotus™
Boston Scientific Corporation (NYSE: BSX) presenta i risultati positivi di un'analisi pre-specificata dei primi 60 pazienti arruolati nello studio REPRISE II, che valuta la performance e la...
-
May 27, 2013In einer Late-Breaking-Session des EuroPCR Kongresses wurden neue Daten zum erfolgreichen Einsatz derLotus™-Aortenklappe für die ersten 60 Patienten der REPRISE II Studie vorgestellt. Nach 30 Tagen traten kaum Fälle einer paravalvulären Aorteninsuffizienz auf.
Die Boston Scientific Corporation (NYSE: Adaptive Seal™" zur Minimierung paravalvulärer Lecks. Letztere sind ein Mortalitätsprädiktor. Die Klappe ist repositionierbar und bergbar (vor dem...
-
May 27, 2013
Die Boston Scientific Corporation (NYSE: BSX) hat positive Ergebnisse zweier Studien zur innovativen Technologie medikamentenfreisetzender Stents (DES), die sich als richtungsweisende Behandlungen...